England’s NICE Backs Epidyolex For Seizures, Sativex For MS Spasticity

But New Guidance Rejects Cannabis-Based Drugs For Chronic Pain

Health technology assessment body NICE has given the thumbs-up to Epidyolex and Sativex, which become the first plant-derived medicinal cannabis products to secure routine NHS funding. It has also issued positive guidance on other products including nabilone, but turned down the use of cannabis-based drugs in chronic pain.

Medical Marijuana D. Medical marijuana pouring out of a prescription bottle against white.
NICE has OKd the first two plant-derived medicinal cannabis products • Source: Shutterstock

England’s health technology assessment body, NICE, has issued final guidance recommending the use of GW Pharmaceuticals’ Epidyolex (cannabidiol/CBD) for seizures associated with two rare conditions, Lennox-Gastaut syndrome and Dravet’s syndrome. In doing so, NICE has reversed its earlier advice against using the drug on the National Health Service for these indications.

NICE has also changed its stance on GW’s Sativex spray (cannabidiol plus tetrahydrocannabinol), and is now recommending its use in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United Kingdom

More from Europe